IP59-14: Patient and Physician Factors Associated with Adjuvant Pembrolizumab Utilization in the Setting of Surgically Resected Clear Cell Renal Cell Carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM · 1 hr. 59 min. (America/New_York)
147A
Abstract
Log in
See all the content and easy-to-use features by logging in or registering!